HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

STAT+: FDA wants to exclude weight loss drugs from a compounding list

FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

By STAT News · Apr 30, 2026 · via STAT News
STAT+: FDA wants to exclude weight loss drugs from a compounding list

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News →

Tags
policyformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Purdue Pharma’s Dissolution Approved, Closing Chapter in OxyContin Legal Case
PolicyBriefing
Purdue Pharma’s Dissolution Approved, Closing Chapter in OxyContin Legal Case
A judge approved Purdue Pharma’s criminal sentence, clearing the way for the company’s dissolution after years…
May 1, 2026
PolicyAJMC ↗
…
Apr 30, 2026
Supreme Court questions how far generics makers can go with 'skinny label' drugs
PolicyEndpoints News ↗
Supreme Court questions how far generics makers can go with 'skinny label' drugs
WASHINGTON — Supreme Court justices gave a few hints about how they intend to rule in a divisive case for the …
Apr 30, 2026